Expression Profile of Human Fc Receptor-Like 1, 2, and 4 Molecules in Peripheral Blood Mononuclear Cells of Patients with Hashimoto’s Thyroiditis and Graves’ Disease

Abstract

Recently identified Fc receptor-like (FCRL) molecules are new members of the immunoglobulin superfamily dominantly expressed by B cells. Although FCRL expression patterns have been studied in normal and malignant cells, their biological functions and roles remain to be clearly identified in humans. Research has particularly focused on FCRL gene polymorphisms in autoimmune diseases, however, their involvement in the pathogenesis of autoimmune diseases is an interesting field for investigation. In the present study, we have investigated the gene expression profiles of FCRL1, 2, and 4 in 2 common thyroid diseases, Hashimoto’s thyroiditis (HT) and Graves’ disease (GD). FCRL1, 2, and 4 expressions were determined in peripheral blood samples of 55 HT patients, 40 GD patients and equal numbers of normal subjects by quantitative real-time PCR. Our results showed downregulation of FCRL1 and upregulation of FCRL2 transcripts in both HT and GD groups compared to healthy counterparts. Overexpression of FCRL4 was observed only in GD patients compared to controls. A significant correlation was observed between all FCRL gene expression levels in HT patients. Only FCRL2 and 4 had a correlation in GD patients. In addition, FCRL1, 2, and 4 gene expressions showed no correlations with the level of anti-thyroid peroxidase antibody (anti-TPO) or anti-thyroglobulin (anti-Tg) antibody from patients’ sera. In conclusion, expressions of activating or inhibitory FCRL1, 2, and 4 showed significant alterations in HT and GD patients compared to healthy subjects.

Key words

FCRL - gene expression - Graves’ disease - Hashimoto’s thyroiditis - mRNA - real-time PCR

• References

• 1 LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008; 112: 1570-1580
• 2 Khan WN. B cell receptor and BAFF receptor signaling regulation of B cell homeostasis. J Immunol 2009; 18: 3561-3567
• 3 Davis RS. Fc receptor-like molecules. Annu Rev Immunol 2007; 25: 525-560
• 4 Nakayama Y, Weissman SM, Bothwell AL. BXMAS1 identifies a cluster of homologous genes differentially expressed in B cells. Biochem Biophys Res Commun 2001; 285: 830-837
• 5 Daëron M, Jaeger S, Du Pasquier L, Vivier E. Immunoreceptor tyrosine-based inhibition motifs: a quest in the past and future. Immunol Rev 2008; 224: 11-43
• 6 Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol 2012; 188: 4741-4745
• 7 Schreeder DM, Cannon JP, Wu J, Li R, Shakhmatov MA, Davis RS. Cutting edge: FcR-like 6 is an MHC class II receptor. J Immunol 2010; 185: 23-27
• 8 Kazemi T, Asgarian-Omran H, Hojjat-Farsangi M, Shabani M, Memarian A, Sharifian RA, Razavi SM, Jeddi-Tehrani M, Rabbani H, Shokri F. Fc receptor-like 1–5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. Int J Cancer 2008; 123: 2113-2119
• 9 Kazemi T, Asgarian-Omran H, Memarian A, Shabani M, Sharifian RA, Vossough P, Ansaripour B, Rabbani H, Shokri F. Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia. Cancer Immunol Immunother 2009; 58: 989-996
• 10 Wang K, Pei H, Huang B, Yang R-L, Wu H-Y, Zhu X, Zhu L. Overexpression of Fc receptor-like 1 associated with B-cell activation during hepatitis B virus infection. Braz J Med Biol Res 2012; 45: 1112-1118
• 11 Simmonds M, Heward J, Carr-Smith J, Foxall H, Franklyn J, Gough S. Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves’ disease. J Clin Endocrinol Metab 2006; 91: 1056-1061
• 12 Zeng Z, Duan Z, Zhang T, Wang S, Li G, Mei Y, Gao J, Ge R, Ye D, Zou Y, Xu S, Xu J, Zhang L, Pan F. Association of FCRL4 polymorphisms on disease susceptibility and severity of ankylosing spondylitis in Chinese Han population. Clin Rheumatol 2012; 31: 1449-1454
• 13 Matesanz F, Fernández O, Milne RL, Fedetz M, Leyva L, Guerrero M, Delgado C, Lucas M, Izquierdo G, Alcina A. The high producer variant of the Fc-receptor like-3 (FCRL3) gene is involved in protection against multiple sclerosis. J Neuroimmunol 2008; 195: 146-150
• 14 Begovich AB, Chang M, Schrodi SJ. Meta-analysis evidence of a differential risk of the FCRL3 −169T→C polymorphism in white and East Asian rheumatoid arthritis patients. Arthritis Rheum 2007; 56: 3168-3171
• 15 Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: Autoimmune thyroid disease: old and new players. Eur J Immunol 2014; 170: 241-252
• 16 Jayakumar R. Clinical approach to thyroid disease. JAPI 2011; 59: 11-13
• 17 Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev 2014; 13: 391-397
• 18 Brent GA. Clinical practice. Graves’ disease. N Engl J Med 2008; 12: 2594-2605
• 19 Ginsberg J. Diagnosis and management of Graves’ disease. CMAJ 2003; 4: 575-585
• 20 Gauld SB, Dal Porto JM, Cambier JC. B cell antigen receptor signaling: roles in cell development and disease. Science 2002; 296: 1641-1642
• 21 Shabani M, Bayat AA, Jeddi-Tehrani M, Rabbani H, Hojjat-Farsangi M, Ulivieri C, Amirghofran Z, Baldari CT, Shokri F. Ligation of human Fc receptor like-2 (FCRL2) by monoclonal antibodies downregulates B cell receptor mediated signaling. Immunol 2014; 143: 341-353
• 22 Baranov KO, Volkova OIu, Mechetina LV, Chikaev NA, Reshetnikova ES, Nikulina GM, Taranin AV, Naiakshin AM. Expression of human B-Cell specific receptor FCRL1 in healthy individuals and in patients with autoimmune diseases. Mol Biol 2012; 46: 450-456
• 23 Shabani M, Hemmati A, Zandemami M, Khoshnoodi J, Jeddi-Tehrani M, Rabbani H, Amirghofran Z, Skokri F. Cloning, Expression and Characterization of Recombinant Human Fc Receptor Like 1, 2 and 4 Molecules. Iran J Biotechnol 2013; 11: 182-192
• 24 Jackson TA, Haga CL, Ehrhardt GR, Davis RS, Cooper MD. FcR-like 2 Inhibition of B cell receptor-mediated activation of B cells. J Immunol 2010; 185: 7405-7412
• 25 Leyendeckers H, Voth E, Schicha H, Hunzelmann N, Banga P, Schmitz J. Frequent detection of thyroid peroxidase-specific IgG+ memory B cells in blood of patients with autoimmune thyroid disease. Eur J Immunol 2002; 32: 3126-3132
• 26 Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P, Yen L, Tan C, Hongo JA, Koeppen H, Ebens A. Expression pattern of the human FcRH/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol 2006; 18: 1363-1373
• 27 Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, Roby G, Kottilil S, Arthos J, Proschan MA, Chun TW, Fauci AS. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008; 205: 1797-1805
• 28 Weiss GE, Crompton PD, Li S, Walsh LA, Moir S, Traore B, Kayentao K, Ongoiba A, Doumbo OK, Pierce SK. Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. J Immunol 2009; 183: 2176-2182
• 29 Yeo L, Lom H, Juarez M, Snow M, Buckley CD, Filer A, Raza K, Scheel-Toellner D. Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann Rheum Dis 2014; DOI: 10.1136/annrheumdis-2013-204116. [Epub ahead of print]
• 30 Zeng Z, Duan Z, Zhang T, Wang S, Li G, Mei Y, Gao J, Ge R, Ye D, Zou Y, Xu S, Xu J, Zhang L, Pan F. Association of FCRL4 polymorphisms on disease susceptibility and severity of ankylosing spondylitis in Chinese Han population. Clin Rheumatol 2012; 31: 1449-1454
• 31 Zhao SX, Liu W, Zhan M, Song ZY, Yang SY, Xue LQ, Pan CM, Gu ZH, Liu BL, Wang HN, Liang L, Liang J, Zhang XM, Yuan GY, Li CG, Chen MD, Chen JL, Gao GQ, Song HD. A refined study of FCRL genes from a genome-wide association study for Graves’ disease. PLoS One 2013; 8: e57758